U.S. markets closed
  • S&P Futures

    -8.00 (-0.22%)
  • Dow Futures

    -50.00 (-0.17%)
  • Nasdaq Futures

    -13.75 (-0.12%)
  • Russell 2000 Futures

    -3.20 (-0.19%)
  • Crude Oil

    +0.30 (+0.38%)
  • Gold

    -6.80 (-0.41%)
  • Silver

    -0.24 (-1.27%)

    -0.0026 (-0.27%)
  • 10-Yr Bond

    -0.0110 (-0.30%)
  • Vix

    +2.57 (+9.40%)

    -0.0283 (-2.61%)

    +0.4790 (+0.33%)

    -50.91 (-0.27%)
  • CMC Crypto 200

    -10.35 (-2.33%)
  • FTSE 100

    -140.92 (-1.97%)
  • Nikkei 225

    -566.34 (-2.09%)

Trade Alert: The President Of Angion Biomedica Corp. (NASDAQ:ANGN), Jay Venkatesan, Has Just Spent US$730k Buying 24% More Shares

·3 min read

Those following along with Angion Biomedica Corp. (NASDAQ:ANGN) will no doubt be intrigued by the recent purchase of shares by Jay Venkatesan, President of the company, who spent a stonking US$730k on stock at an average price of US$2.63. Not only is that a big swing, but it increased their holding size by 24%, which is definitely great to see.

Check out our latest analysis for Angion Biomedica

Angion Biomedica Insider Transactions Over The Last Year

Notably, that recent purchase by Jay Venkatesan is the biggest insider purchase of Angion Biomedica shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$2.96. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Happily, we note that in the last year insiders paid US$1.0m for 404.00k shares. But insiders sold 1.40k shares worth US$28k. In the last twelve months there was more buying than selling by Angion Biomedica insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!


Angion Biomedica is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Angion Biomedica insiders own about US$12m worth of shares. That equates to 14% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The Angion Biomedica Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. When combined with notable insider ownership, these factors suggest Angion Biomedica insiders are well aligned, and that they may think the share price is too low. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that Angion Biomedica has 4 warning signs (1 is a bit unpleasant!) that deserve your attention before going any further with your analysis.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.